Table 3 Randomized Trials of Biologically Targeted Therapies in Pancreatic NET
From: Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
Regimen | N (total) | Overall Response Rate | Median Progression-Free Survival/TTP | P value | Reference |
|---|---|---|---|---|---|
Sunitinib (37.5 mg po qd) Placebo (+ best supportive care) | 171 | 9% 0% | 11.4 months 5.5 months | .0001 | Raymond et al, 2011 [61] |
Everolimus (10 mg po qd) Placebo (+ best supportive care) | 410 | 5% 2% | 11 months 4.6 months | <.0001 | Yao et al, 2011 [65] |
Everolimus (10 mg po qd) Everolimus (10 mg po qd) + Bevacizumab (10 mg/kg every other week) | CALGB 80701 | (Ongoing) | Â | Â | Â |